Trump's tariff threat on generic drugs: Why this matters for Indian pharma companies

📌 Summary:

• Context: On July 21, US President Trump said tariffs on generic drugs will be raised 100% after two years and 200% thereafter to "reshore" generic pharma production; companies not building US plants will be "penalised"
• Caveat: Actual drug tariffs have been exempted in most instruments Trump has used so far (IEEPA, Section 122 of the 1974 Trade Act, Section 232 of the 1962 Trade Expansion Act); experts say the threats mainly aim to attract investment to the US, not raise tariffs, especially before midterm elections
• Why it matters for India: The US is India's largest pharma export market (~40% share); ~90% of India's pharma exports to the US are generics; India exported $9.7 billion of pharmaceuticals to the US in 2025
• Scale of US market: US imported $213 billion of pharma products in 2025, including $94.1 billion of finished retail medicines (the generics category)
• Investment shift (causal chain): Tariff uncertainty is pushing Indian firms to invest in the US to secure market access — Sun Pharma acquired US-listed Organon & Co. for $11.8 billion (an Indian pharma company's largest overseas acquisition)
• Outbound investment data: India-to-US outbound investment hit $4.08 billion in FY26 (up from $3.44 bn FY25 and $2.44 bn FY24) — pharma outbound this year exceeds the last four years combined; steel firms (e.g., JSW Steel's $500 mn in Ohio/Texas) also stepping up
• Prior threats: April 2, 2026 (up to 100% on branded medicines under Section 232) and Sept 25, 2025 (100% on branded/patented) — neither implemented

🎯 UPSC Relevance: GS2 IR / GS3 Economy — India-US trade relations, pharma exports, tariff policy, and its impact on Indian industry and investment flows.

📝 Prelims Facts:

• US is India's largest pharma export market (~40% share); ~90% of exports are generics
• India's 2025 pharma exports to US: $9.7 billion
• Section 232 (Trade Expansion Act 1962) invokes national security to impose tariffs
• Sun Pharma acquired Organon & Co. for $11.8 billion

🔑 Key Term: Generic drug — a medicine created to be the same as an already-marketed brand-name drug in dosage, safety, strength and intended use, sold after the original patent expires, usually at much lower cost.